Rituximab Biosimilar Prevents Poor Outcomes of Microscopic Polyangiitis and Granulomatosis with Polyangiitis as Effectively as Rituximab Originator

PURPOSE: There has been no extensive study to compare the efficacy between rituximab originator (Mabthera®) and its biosimilar (Truxima®) for microscopic polyangiitis (MPA) and granulomatosis with polyangiitis (GPA). Here, we investigated the clinical effects of rituximab on poor outcomes of MPA and...

Descripción completa

Detalles Bibliográficos
Autores principales: Kwon, Hyeok Chan, Kim, Minyoung Kevin, Song, Jason Jungsik, Park, Yong-Beom, Lee, Sang-Won
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Yonsei University College of Medicine 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7393299/
https://www.ncbi.nlm.nih.gov/pubmed/32734735
http://dx.doi.org/10.3349/ymj.2020.61.8.712

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7393299/
https://www.ncbi.nlm.nih.gov/pubmed/32734735
http://dx.doi.org/10.3349/ymj.2020.61.8.712

Ejemplares similares